A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes (NCT04929379)
🩺 Plain-English Summary (8th-Grade Level)
Diabetic kidney disease remains the leading cause of end-stage kidney disease (ESKD), rising in frequency in parallel with the epidemic of diabetes worldwide. The estimated lifetime risk of kidney disease in persons with type 1 diabetes (T1D) has been reported to be as high as 50-70%, although risk may be lower in excellent care environments. Two previous studies have suggested that a generic drug used to lower fats in blood (fenofibrate) may protect the kidney from damage due to diabetes. These data, however, were obtained among people with type 2 diabetes with clinical characteristics optimized for cardiovascular studies. Thus, a clinical trial specifically designed to evaluate the effects on the kidney is required to firmly show that this drug can prevent kidney damage in T1D. The goals of the present pilot study are to demonstrate the feasibility of such trial, gather essential information for designing and planning this study, and generate preliminary data. To this end, 40 participants with T1D and early-to-moderate diabetic kidney disease (DKD), at high risk of ESKD, will be enrolled at two clinical sites and assigned in a 1:1 ratio to treatment with fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and at the end of the study to evaluate the effect of fenofibrate.
Who can join: Review the eligibility criteria below.
Location: Joslin Diabetes Center — Boston, Massachusetts
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Joslin Diabetes Center — Boston, Massachusetts
- Lahey Hospital and Medical center — Burlington, Massachusetts
- Brehm Center for Diabetes Research / University of Michigan — Ann Arbor, Michigan
- SUNY Upstate Medical University — Syracuse, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Nephropathies
- Formoterol in Diabetes — Charleston, South Carolina
- Study of WAL0921 in Patients With Glomerular Kidney Diseases — Los Angeles, California
- Transformative Research in Diabetic Nephropathy — Little Rock, Arkansas
- Transformative Research in Diabetic Nephropathy 2.0 — Philadelphia, Pennsylvania
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford, California
Explore by condition: All Diabetic Nephropathies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.